What is the next step in managing a patient with chronic insomnia who is already taking lemborexant (Dayvigo) 10 mg, has normal laboratory results, and has an MRI and polysomnography ordered but continues to have inadequate sleep?

Immediate Next Step: Add Cognitive Behavioral Therapy for Insomnia (CBT-I)

Your patient needs CBT-I immediately—this should have been initiated before or alongside pharmacotherapy, and remains the most critical missing intervention. 1

Why CBT-I Must Be Added Now

The 2016 American College of Physicians guideline provides a strong recommendation that all adults with chronic insomnia receive CBT-I as initial treatment 1. Your patient is on lemborexant (Dayvigo) 10 mg without documented behavioral therapy, which represents a fundamental gap in evidence-based care. Pharmacotherapy alone, even with newer agents like lemborexant, should be supplemented with behavioral and cognitive therapies whenever possible 2.

The evidence is clear: CBT-I produces durable improvements that persist beyond treatment cessation, unlike medications which often lose efficacy after discontinuation 3. Multiple guidelines from 2008-2021 consistently emphasize that psychological/behavioral interventions are standard treatment for chronic insomnia 2, 4.

Specific CBT-I Components to Implement

Refer your patient for multicomponent CBT-I that includes 2:

• Stimulus control therapy: Go to bed only when sleepy; leave bed if unable to sleep within ~20 minutes; use bed only for sleep; maintain regular schedule
• Sleep restriction therapy: Initially limit time in bed to match actual total sleep time from sleep diary
• Cognitive therapy: Address maladaptive beliefs like "I can't sleep without medication" or "My life will be ruined if I can't sleep"
• Relaxation training: Progressive muscle relaxation or similar techniques

Delivery options include in-person individual/group therapy, telephone-based, web-based modules, or self-help books 1. If specialized CBT-I providers are unavailable, brief behavioral therapy or individual components (stimulus control, relaxation) are acceptable alternatives 4.

Pharmacotherapy Optimization While Awaiting CBT-I

Evaluate Current Lemborexant Response

The FDA label states: "Call your healthcare provider if your insomnia worsens or is not improved within 7 to 10 days. This may mean that there is another condition causing your sleep problem" 5. Your patient meets this criterion.

Consider These Medication Adjustments:

Option 1: Continue lemborexant while adding CBT-I (preferred)

• Lemborexant shows consistent objective and subjective improvements in sleep onset latency, wake after sleep onset, and total sleep time 6, 7, 8
• Recent meta-analyses confirm efficacy: reduces sleep onset latency by ~10-13 minutes and wake after sleep onset by ~20-22 minutes 6, 8
• Well-tolerated with primarily somnolence as the main adverse effect 6

Option 2: Switch to alternative pharmacotherapy if lemborexant truly ineffective

Following the 2008 AASM sequential medication algorithm 2:

1. Try alternative short-intermediate acting BzRA: Consider eszopiclone, zolpidem, or zaleplon based on symptom pattern

   • If sleep onset is primary: zaleplon (very short half-life)
   • If sleep maintenance is primary: eszopiclone or temazepam (longer half-life)

2. If BzRAs unsuccessful, consider sedating antidepressants: Trazodone, low-dose doxepin (FDA-approved for insomnia), amitriptyline, or mirtazapine—especially if comorbid depression/anxiety exists 2

3. Combination therapy: BzRA + sedating antidepressant may be considered 2

Critical Diagnostic Reassessment

Before changing medications, actively investigate occult comorbid disorders 2:

Await Your Ordered Studies:

• Polysomnography: Essential to rule out sleep apnea (found in 75% of treatment-resistant insomnia patients taking nightly medications) 9 and periodic limb movements
• MRI: Appropriate if neurological causes suspected

Evaluate for Psychiatric Comorbidities:

• Depression screening (PHQ-9)
• Anxiety disorders (GAD-7)
• Substance use history
• The FDA label warns that worsening depression and suicidal thoughts can occur with lemborexant—actively screen for this 5

Medication Review:

• Identify drugs that may worsen insomnia (stimulants, corticosteroids, beta-blockers, SSRIs)
• Assess for drug interactions affecting lemborexant metabolism
• Confirm she's not taking lemborexant with/after meals (delays absorption) 5

Sleep Hygiene Assessment:

While sleep hygiene alone is not recommended as monotherapy 2, verify she's avoiding:

• Alcohol (contraindicated with lemborexant per FDA label) 5
• Excessive caffeine
• Irregular sleep schedules
• Screen time before bed

Monitoring and Follow-Up Algorithm

Immediate (next 2-4 weeks):

• Initiate CBT-I referral
• Continue lemborexant 10 mg
• Collect sleep diary data daily
• Review polysomnography and MRI results when available
• Reassess every 2-4 weeks initially 2

If no improvement after 4-6 weeks of CBT-I + lemborexant:

• Consider switching to alternative BzRA or adding sedating antidepressant
• Re-evaluate for missed comorbid disorders 2
• Assess CBT-I adherence and treatment fidelity

Long-term (6+ months):

• Monitor every 6 months as relapse rate is high 2
• Attempt medication tapering once stable (CBT-I facilitates this) 2
• Chronic medication may be indicated for severe/refractory cases 2

Common Pitfalls to Avoid

1. Don't simply increase lemborexant dose without adding CBT-I—this violates guideline-based care
2. Don't switch medications before ruling out sleep apnea—75% of treatment-resistant patients have undiagnosed OSA 9
3. Don't use sleep hygiene education alone—insufficient evidence for efficacy 2
4. Don't prescribe OTC antihistamines or melatonin—not recommended due to lack of efficacy/safety data 2
5. Don't forget to assess for complex sleep behaviors (sleep-walking, sleep-driving)—these require immediate discontinuation 5